Anadrol vs Pramipexole
FDA Approved vs FDA Approved
synergistic Mechanism-based · 65% Pramipexole supports hormonal recovery from suppression caused by Anadrol. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
Anadrol Pramipexole
Weight 332.48 Da 211.33 Da
Half-life ~8-9 hours ~8 hours
Type 17-alpha alkylated anabolic steroid (C21H32O3) Non-ergoline dopamine D3 receptor agonist
Key Benefits
Anadrol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Exceptional strength gains, often noticeable within the first week
03 Potent stimulation of erythropoietin and red blood cell production
04 Increased appetite and nutrient partitioning in some users
05 Improved recovery between training sessions
06 Full, round muscle appearance due to intramuscular water and glycogen retention
07 FDA-approved treatment for various forms of anemia
Pramipexole
01 Suppresses prolactin elevation caused by 19-nor anabolic steroids
02 Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline
03 Generally cheaper and more widely available than cabergoline
04 FDA-approved with a well-characterized safety and pharmacokinetic profile
05 Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles
06 Viable alternative when cabergoline cannot be sourced
Side Effects
Anadrol
Significant water retention and bloating (estrogenic, not aromatase-mediated)
Elevated blood pressure (fluid volume and RBC increase)
Severe liver stress and elevated liver enzymes (AST/ALT)
Back pumps and lower back pain during exercise
Headaches (often blood pressure-related)
Appetite suppression (paradoxical for a mass-building compound)
Lethargy and fatigue (hepatic strain-related)
Acne and oily skin
Suppression of natural testosterone production
Pramipexole
Nausea (very common during initiation; typically resolves with continued use)
Drowsiness and somnolence (often taken at bedtime to manage this)
Dizziness or lightheadedness
Headache
Insomnia (in some users, despite drowsiness being more typical)
Orthostatic hypotension (feeling faint when standing up quickly)
Contraindications
Pre-existing liver disease or significantly elevated liver enzymes
Prostate cancer or breast cancer in males
Nephrotic phase of nephritis
Hypercalcemia (Anadrol can exacerbate calcium levels)
Pregnancy (Category X - causes virilization of the female fetus)
Known hypersensitivity to oxymetholone
Concurrent use of other 17-alpha alkylated oral steroids (compounded liver toxicity)
Known hypersensitivity to pramipexole or any component of the formulation
Concurrent use of other dopamine agonists (cabergoline, bromocriptine)
History of impulse control disorders or pathological gambling
Severe renal impairment (pramipexole is primarily renally excreted; dose adjustment required in moderate impairment)
Concurrent use of dopamine antagonists (antipsychotics, metoclopramide) which oppose pramipexole's mechanism
Research Evidence
Anadrol Pramipexole
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2018 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.